Knight Therapeutics Advances Parkinson’s Disease Treatment in Mexico
Knight Therapeutics Inc., a dedicated specialty pharmaceutical company operating throughout Latin America, is making waves in the treatment of Parkinson's disease with its recent submission for the marketing authorization of CREXONT® (Carbidopa and Levodopa) extended-release capsules. This submission was made by Knight's Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., to COFEPRIS, the health regulatory authority in Mexico. This step marks a critical move in addressing the pressing medical needs of patients suffering from Parkinson’s Disease.
Understanding CREXONT® and Its Benefits
CREXONT® represents a significant innovation in the realm of Parkinson’s treatment. It is formulated as an oral capsule, uniquely combining both immediate-release and extended-release properties to optimize therapeutic outcomes. Specifically designed to enhance patient convenience, this formulation allows for effective management of Parkinson’s disease symptoms throughout the day. The extended-release mechanism ensures that patients receive a steady dose of medication, promoting better overall management of their condition.
Results from Clinical Trials
CENTRAL to the efficacy claims of CREXONT® is data from the RISE-PD clinical study, which involved 630 participants in a randomized, double-blind, and active-controlled phase 3 trial. This comprehensive study demonstrated that patients treated with CREXONT® experienced a significant increase in daily "Good On" time, which refers to periods when patients are likely to be free from motor symptoms. Notably, CREXONT® was associated with an increase of over half an hour more than those receiving traditional immediate-release Carbidopa and Levodopa, significantly improving patients' quality of life.
Meeting a Critical Medical Need
The urgency surrounding this submission is underscored by the multiplying number of cases of Parkinson’s disease globally. In fact, it has become the fastest-growing neurological condition. With approximately one million diagnoses in the United States alone and around 500,000 individuals affected in Mexico, the need for effective treatment options has never been more evident. The reality of living with Parkinson's disease is fraught with challenges, including slowness of movement, stiffness, resting tremors, and balance impairment, which significantly impact daily living.
A Commitment to Neurology
Samira Sakhia, President and CEO of Knight Therapeutics, expressed strong commitment in pursuing new therapeutic avenues for neurologic disorders. She stated, “This submission of CREXONT® in Mexico demonstrates Knight’s continued execution of our strategy to expand our neurology portfolio. There is a high unmet medical need in the treatment of Parkinson’s disease, and we are confident that, with CREXONT®, we will be bringing a much-needed novel treatment option to Parkinson’s patients.”
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. focuses on developing and commercializing innovative pharmaceutical solutions for patients in Latin America. The company operates under various brands, including United Medical and Biotoscana Farma, ensuring a broad reach across the region. Knight’s dedication to enhancing patient outcomes aligns with a long-term vision of healthcare advancement.
Frequently Asked Questions
What is CREXONT® and how does it work?
CREXONT® is an extended-release capsule formulation of Carbidopa and Levodopa designed to treat Parkinson’s disease effectively throughout the day by combining both immediate and extended-release actions.
What are the primary benefits of using CREXONT®?
This medication significantly improves daily “Good On” time for patients, allowing them to experience optimum symptom control with fewer doses throughout the day.
Why is the CREXONT® submission important?
The submission is crucial as it addresses a high unmet need for effective treatments in the growing population of Parkinson’s patients in Mexico and broader Latin America.
Who is behind the development of CREXONT®?
CREXONT® is being developed by Knight Therapeutics Inc., in collaboration with Amneal Pharmaceuticals, which holds exclusive rights for commercialization in Canada and Latin America.
What trends are seen in Parkinson’s disease globally?
Parkinson’s disease is on the rise as one of the fastest-growing neurological disorders, with increasing diagnoses due to aging populations and heightened awareness of the disease.
